Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis

Martin M. Herrmann¹, Silvia Barth¹, Bernhard Greve¹, Kathrin M. Schumann¹, Andrea Bartels¹ and Robert Weissert¹,²,*

ABSTRACT

After encounter with a central nervous system (CNS)-derived autoantigen, lymphocytes leave the lymph nodes and enter the CNS. This event leads only rarely to subsequent tissue damage. Genes relevant to CNS pathology after cell infiltration are largely undefined. Myelin-oligodendrocyte-glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS), a chronic autoimmune disease of the CNS that results in disability. To assess genes that are involved in encephalitogenicity and subsequent tissue damage mediated by CNS-infiltrating cells, we performed a DNA microarray analysis from cells derived from lymph nodes and eluted from CNS in LEW.1AV1 (RT1av1) rats immunized with MOG 91-108. The data was compared to immunizations with adjuvant alone or naive rats and to immunizations with the immunogenic but not encephalitogenic MOG peptide 73-90, were immunogenic, showing strong Th1 responses, but were not encephalitogenic. The induction of active EAE in LEW.1AV1 rats immunized with MOG 91-108 was dissociated in regard to Th1 or Th2 cytokine expression in lymphoid tissue compared to the CNS. Moreover, different MOG 1-125-derived peptides, such as MOG 73-90, were immunogenic, showing strong Th1 responses, but were not encephalitogenic. The induction of active EAE in LEW MHC congenic rat strains and Dark Agouti (DA) (RT1av1) rats does not require the application of pertussis toxin like in mice. This is an advantage because the exact role of pertussis toxin in EAE induction is not clear so far. Pertussis toxin inhibits GI proteins and thereby influences multiple cellular processes and pathways (Dumas et al., 2014). Active EAE in susceptible rat strains is induced by immunization with an encephalitogenic peptide mixed with mineral oil [incomplete Freund’s adjuvant (IFA)] with the addition of heat-inactivated mycobacterium tuberculosis (MT) as adjuvant [complete Freund’s adjuvant (CFA)]. MT leads by binding and signaling through Toll-like receptors (TLRs) to an activation program in a number of cell types and is also a systemic ‘danger signal’ (Mills, 2011).

In regard to susceptibility to EAE and MS, gene expression profiling studies have been performed to elucidate genes that are involved in disease pathogenesis. A number of interesting genes were described, such as osteopontin (Hur et al., 2007). In no study was a systematic comparison of gene expression profiles performed in EAE in which the influence of adjuvant and antigen was systematically compared on the expression profile of lymph node (LN)-derived cells or cells eluted from CNS of diseased animals. In the present study, we systematically compared the gene expression profiles of cells from draining LNs and CNS-infiltrating cells that were eluted in LEW.1AV1 (RT1av1) rats immunized with MOG 91-108 in CFA, CFA alone and in naive rats. Moreover, we compared the gene expression profile of rats immunized with the encephalitogenic MOG peptide 91-108 with rats immunized with the non-encephalitogenic MOG peptide 73-90. We found differentially expressed genes that are of major importance for...
encephalitogenicity. The influence of these genes was subsequently verified by different means.

RESULTS

Gene expression after immunization with encephalitogenic and non-encephalitogenic peptides

One of the important issues in MS and other inflammatory diseases of the CNS is understanding the requisites of autoantigenic peptides to induce CNS inflammation (Riedhammer and Weissett, 2015). Beside presentation of autoantigen-derived peptides on MHC molecules and the availability of reactive T-cell and B-cell repertoires as well as the presence of the target antigen in the CNS, pathways of cellular activation exist that allow disease development. These pathways are presently only partly elucidated. We used MOG-induced EAE in LEW.1AV1 (RT1^av1^) rats as a model system for CNS inflammation. In this EAE model, the determinant MOG 91-108 is immunogenic and encephalitogenic. In contrast, the determinant MOG 73-90 is immunogenic but not encephalitogenic. We assessed the gene expression profiles by gene arrays of lymphocytes from draining LNs and from lymphocytes eluted from the CNS.

To focus on genes that are truly relevant to encephalitogenicity and not simply involved in general inflammatory responses, we compared gene arrays of LEW.1AV1 (RT1^av1^) rats immunized with the encephalitogenic MOG stretch MOG 91-108 to naive LEW.1AV1 (RT1^av1^) rats and rats immunized with the adjuvant CFA alone as well as rats immunized with the non-encephalitogenic MOG 73-90 determinant. We analyzed ten comparisons for each of the naive and CFA groups versus MOG 91-108 and five comparisons for MOG 73-90 versus MOG 91-108. The number of comparisons in which a given gene had a signal log ratio (SLR) of above 1 was counted. In Table 1, we show genes that are upregulated in at least half of the comparisons (n=50%). Besides Cxcr4 and Cd38, which were subsequently analyzed in greater detail, many genes with a known function in EAE and MS pathology were found to have an increased expression in MOG 91-108-immunized rats as compared to controls. This validates our gene list and supports the relevance of the genes not previously described in EAE. In Table S1, genes with decreased expression in EAE are listed. In this analysis, the variability between gene arrays was much higher and fewer genes were found to be regulated with a clear pattern according to our criteria.

Comparisons of microarrays of CNS-infiltrating lymphocytes derived from LEW.1AV1 (RT1^av1^) rats after immunization with MOG 91-108, MOG 73-90 and CFA alone resulted in many more genes being differentially expressed as compared to the analysis of LN cells (Tables S2 and S3). This could mirror the influx of different cell populations into the CNS during an inflammatory attack. Similar to the analysis of LN cells, we found that Cd38 and Cxcr4 mRNA was strongly increased in CNS-infiltrating cells.

Subsequently, we analyzed purified CD4^+^ cells from LNs and CNS of MOG 91-108- and MOG 73-90-immunized rats. To some extent, similar gene expression profiles were found in the purified CD4^+^ cell population compared to non-separated LN cells (Table 1, Tables S4 and S5).

Owing to their strong expression in MOG 91-108-immunized rats compared to naive, CFA-immunized and MOG 73-90-immunized rats, we chose Cxcr4 and Cd38 for further analysis.

Cxcr4 and Cd38 in EAE in LEW.1AV1 (RT1^av1^) rats

Confirming our microarray results by quantitative PCR, we found a significant upregulation of Cxcr4 expression in LN cells of MOG 91-108-immunized rats (n=8) as compared to CFA-immunized (n=8, ANOVA, P<0.0001) and naive (n=6, ANOVA, P<0.0001) LEW.1AV1 (RT1^av1^) rats (Fig. 1A). Also, an increased expression of Cd38 was measured [MOG 91-108-immunized rats (n=8) as compared to CFA-immunized (n=8, ANOVA, P<0.05) and naive (n=6, ANOVA, P<0.05) LEW.1AV1 (RT1^av1^) rats].

In cells eluted from the CNS, we found upregulation of Cxcr4 (Fig. 1B) and Cd38 (Fig. 1C) in MOG 91-108-immunized LEW.1AV1 (RT1^av1^) rats (n=6) compared to rats immunized with MOG 73-90 (n=6, ANOVA, Cxcr4 and Cd38 each P<0.001) or CFA alone (n=6, ANOVA, Cxcr4 and Cd38 each P<0.001).

Cxcr4 and Cxcl12 expression in spinal cord of DA (RT1^av1^) rats

Next, we assessed the mRNA expression of Cxcr4 (Fig. 2A) and its ligand Cxcl12 (Fig. 2B) in spinal cord of either naive DA (RT1^av1^) rats or DA (RT1^av1^) rats immunized with IFA or CFA alone or MOG 1-125 in IFA or MOG 1-125 in CFA (each n=4). Upregulation of both Cxcl12 and Cxcr4 mRNA expression was observed in CFA- and MOG 1-125 in CFA-immunized DA (RT1^av1^) rats in spinal cord compared to naive rats, IFA-injected or MOG 1-125 in IFA-immunized DA (RT1^av1^) rats (ANOVA, P<0.001). Increased Cxcl12 and Cxcr4 mRNA expression was observed in MOG 1-125 in CFA- compared to CFA-immunized DA (RT1^av1^) rats (ANOVA, P<0.01).

Cxcr4 and Cxcl12 in individuals with MS

Upregulation of CXC4 mRNA was also observed in white blood cells of individuals with MS with a relapsing-remitting disease course (RRMS; n=32) and a secondary chronic progressive disease course (SPMS; n=22), and compared to controls (n=25, ANOVA, RRMS and SPMS each P<0.05) (Fig. 3A, Tables S6 and S7). Also, we detected increased protein CXL12 serum levels in both individuals with RRMS (n=24) and SPMS (n=28) compared to controls (n=21, ANOVA, RRMS and SPMS each P<0.05) (Fig. 3B, Tables S6 and S7).

EAE in B6.129P2-Cd38tm1Lnd/J mice

Cd38 was strongly upregulated in encephalitogenic LN cells. To functionally validate our data and to elucidate the role of CD38 in EAE, we induced disease with the extracellular domain of MOG (MOG 1-125) in Cd38-knockout (B6.129P2-Cd38^gmoLnd/J) mice and appropriate controls. We found reduced disease severity in MOG 1-125-immunized B6.129P2-Cd38^gmoLnd/J mice (n=22) compared to wild-type control mice (n=21, t-test, cumulative disease score P<0.01) (Fig. 4A). Next, we determined the height of the antibody response to MOG 1-125. Reduced anti-MOG IgG autoantibody responses in B6.129P2-Cd38^gmoLnd/J mice (n=4) compared to wild-type control mice (n=4, ANOVA, P<0.05) after immunization with MOG 1-125 were seen (Fig. 4B) on day 12 post-immunization (p.i.). Furthermore, also T-cell responses upon restimulation with MOG 1-125 were reduced in the B6.129P2-Cd38^gmoLnd/J mice (n=4) on day 12 p.i. compared to control mice (n=4, t-test for stimulation with 50 µg/ml MOG 1-125, P<0.05) as measured in a proliferation assay, indicating in addition a T-cell priming or expansion defect in B6.129P2-Cd38^gmoLnd/J mice (Fig. 4C).

Targeting cellular migration by FTY720

We found an upregulation of Akt in our differential gene expression studies (Table 1). FTY720 is a 5′-P receptor modulator known to influence T-cell trafficking by an Akt-dependent mechanism, as
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hmgcs2</td>
<td>3-hydroxy-3-methylglutaryl-CoA synthase 2</td>
<td>M3648_g_at</td>
<td>100</td>
<td>3.27</td>
<td>100</td>
<td>1.39</td>
<td>100</td>
<td>2.15</td>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ptpn16</td>
<td>Protein tyrosine phosphatase non- (\alpha) type 16</td>
<td>U02553cds_s_at</td>
<td>100</td>
<td>3.22</td>
<td>80</td>
<td>1.87</td>
<td>100</td>
<td>3.00</td>
<td>Intracellular signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cxcr4</td>
<td>Chemokine receptor (LCR1)</td>
<td>rc_AA945737_at</td>
<td>100</td>
<td>1.94</td>
<td>80</td>
<td>1.48</td>
<td>100</td>
<td>1.67</td>
<td>Chemokine receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ccl3</td>
<td>Chemokine (C-C motif) ligand 3</td>
<td>U22414_at</td>
<td>90</td>
<td>2.68</td>
<td>70</td>
<td>1.86</td>
<td>60</td>
<td>0.72</td>
<td>Chemokine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jun</td>
<td>v-jun sarcoma virus 17 oncogene homolog</td>
<td>rc_A175959_at</td>
<td>80</td>
<td>2.19</td>
<td>100</td>
<td>2.95</td>
<td>60</td>
<td>1.12</td>
<td>Intracellular signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cd38</td>
<td>CD38 antigen</td>
<td>rc_AA191878_s_at</td>
<td>60</td>
<td>1.75</td>
<td>100</td>
<td>2.62</td>
<td>60</td>
<td>0.98</td>
<td>Ectoenzyme cADPR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cxcl2</td>
<td>Chemokine (C-X-C motif) ligand 2</td>
<td>U49065_at</td>
<td>50</td>
<td>2.79</td>
<td>60</td>
<td>2.96</td>
<td>100</td>
<td>2.21</td>
<td>Cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itg6</td>
<td>Interleukin 1 beta</td>
<td>E01884cds_s_at</td>
<td>100</td>
<td>6.63</td>
<td>80</td>
<td>2.21</td>
<td>100</td>
<td>2.13</td>
<td>Chemokine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceptbp</td>
<td>CCAAT/enhancer binding protein (C/EBP), beta</td>
<td>S77528cds_s_at</td>
<td>100</td>
<td>4.64</td>
<td>80</td>
<td>1.32</td>
<td>100</td>
<td>2.68</td>
<td>Cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ass</td>
<td>Argininosuccinate synthetase</td>
<td>X12459_at</td>
<td>100</td>
<td>4.55</td>
<td>60</td>
<td>1.77</td>
<td>100</td>
<td>2.15</td>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arg1</td>
<td>Arginase 1</td>
<td>J02720_at</td>
<td>100</td>
<td>4.36</td>
<td>50</td>
<td>1.43</td>
<td>100</td>
<td>2.68</td>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fcgr3</td>
<td>Fc receptor, IgG, low affinity III</td>
<td>M32062_g_at</td>
<td>100</td>
<td>4.26</td>
<td>80</td>
<td>1.86</td>
<td>100</td>
<td>2.26</td>
<td>Complement receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ptgs2</td>
<td>Prostaglandin-endoperoxide synthase 2</td>
<td>S67722_s_at</td>
<td>100</td>
<td>3.96</td>
<td>60</td>
<td>1.96</td>
<td>100</td>
<td>2.21</td>
<td>Cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spp1</td>
<td>Secreted phosphoprotein 1</td>
<td>M14656_at</td>
<td>100</td>
<td>3.49</td>
<td>50</td>
<td>1.13</td>
<td>100</td>
<td>2.15</td>
<td>Inflammation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olr1</td>
<td>Oxidised low density lipoprotein receptor 1</td>
<td>rc_A1071531_s_at</td>
<td>100</td>
<td>3.37</td>
<td>80</td>
<td>2.04</td>
<td>100</td>
<td>2.21</td>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nos2</td>
<td>Nitric oxide synthase 2, inducible</td>
<td>U03699complete_seq_at</td>
<td>100</td>
<td>3.19</td>
<td>80</td>
<td>2.71</td>
<td>100</td>
<td>2.21</td>
<td>Inflammation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anpnap</td>
<td>Alanyl (membrane) aminopeptidase</td>
<td>M25073_at</td>
<td>100</td>
<td>3.04</td>
<td>50</td>
<td>1.80</td>
<td>100</td>
<td>2.21</td>
<td>Metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vegf</td>
<td>Vascular endothelial growth factor</td>
<td>rc_AA850734_at</td>
<td>100</td>
<td>2.81</td>
<td>50</td>
<td>1.28</td>
<td>100</td>
<td>2.21</td>
<td>Growth factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Igf6</td>
<td>Immunoglobulin superfamily, member 6</td>
<td>AJ223184_at</td>
<td>100</td>
<td>2.73</td>
<td>50</td>
<td>0.85</td>
<td>100</td>
<td>2.21</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F3</td>
<td>Coagulation factor 3</td>
<td>U07619_at</td>
<td>100</td>
<td>2.32</td>
<td>70</td>
<td>1.54</td>
<td>100</td>
<td>2.21</td>
<td>Coagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edn1</td>
<td>Endothelin 1</td>
<td>M47711_at</td>
<td>90</td>
<td>1.85</td>
<td>50</td>
<td>1.06</td>
<td>90</td>
<td>1.65</td>
<td>Homeostasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wap</td>
<td>Whey acidic protein</td>
<td>J0901_at</td>
<td>60</td>
<td>1.27</td>
<td>90</td>
<td>1.65</td>
<td>60</td>
<td>1.27</td>
<td>Milk protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junb</td>
<td>Jun-B oncogene</td>
<td>X54686cds_at</td>
<td>60</td>
<td>1.24</td>
<td>50</td>
<td>0.94</td>
<td>60</td>
<td>1.27</td>
<td>Transcription</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
Table 1. Continued

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Function (putative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOC286890</td>
<td>Tropomyosin isoform 6</td>
<td>Cell structure</td>
</tr>
<tr>
<td>Cdkn1b</td>
<td>Cyclin-dependent kinase inhibitor 1B</td>
<td>Cell cycle</td>
</tr>
<tr>
<td>Hmgf1</td>
<td>High mobility group box 1</td>
<td>Transcription</td>
</tr>
<tr>
<td>Smst28</td>
<td>Somatostatin receptor 28</td>
<td>Metabolism</td>
</tr>
<tr>
<td>Klf9</td>
<td>Kruppel-like factor 9</td>
<td>Transcription</td>
</tr>
<tr>
<td>Cited2</td>
<td>Cbp/p30-interacting transactivator 2</td>
<td>Transcription</td>
</tr>
<tr>
<td>Akt2</td>
<td>Murine thymoma (v-akt)oncogene homolog 2</td>
<td>Intracellular</td>
</tr>
<tr>
<td>Hba1</td>
<td>Hemoglobin, alpha 1</td>
<td>Metabolism</td>
</tr>
<tr>
<td>Zfp36</td>
<td>Zinc finger protein 36</td>
<td>Cell cycle</td>
</tr>
<tr>
<td>Sv2b</td>
<td>Synaptic vesicle glycoprotein 2 b</td>
<td>Metabolism</td>
</tr>
<tr>
<td>Mmp12</td>
<td>Matrix metalloproteinase 12</td>
<td>Proteases</td>
</tr>
<tr>
<td>Hmox1</td>
<td>Heme oxygenase 1</td>
<td>Unknown</td>
</tr>
<tr>
<td>Klf4</td>
<td>Kruppel-like factor 4 (gut)</td>
<td>Transcription</td>
</tr>
<tr>
<td>Ita</td>
<td>Interleukin 1 alpha</td>
<td>Metabolism</td>
</tr>
<tr>
<td>Slc2a1</td>
<td>Solute carrier family 2, member 1</td>
<td>Extracellular</td>
</tr>
<tr>
<td>Dan1</td>
<td>Decorin</td>
<td>Cell cycle</td>
</tr>
<tr>
<td>Gadd45a</td>
<td>Growth arrest and DNA-damage-induced 45a</td>
<td></td>
</tr>
</tbody>
</table>

LEW.1AV1 (RT1<sup>av1</sup>) rats were immunized with MOG 91-108 in CFA, MOG 73-90 in CFA and CFA alone. Gene expression in lymph node (LN) cells was analyzed using Affymetrix gene arrays. Gene arrays from rats immunized with MOG 91-108 in CFA (pooled samples of at least $n=3$ rats, $n=5$ gene chips) were compared to gene arrays from naive rats (pooled samples, $n=2$ chips), CFA-immunized rats (pooled samples, $n=2$ chips) and MOG 73-90 in CFA-immunized rats (pooled samples, $n=1$ chip) resulting in each ten comparisons for CFA-immunized and naive to MOG 91-108-immunized rats and five for MOG 73-90- to MOG 91-108-immunized rats. The number of comparisons in which a given gene had a signal log ratio (SLR) above 1 were counted. If a gene had an SLR above 1 in 50% of the comparisons it was included in the analysis. ESIs and sequences not corresponding to a gene and duplicates were removed from the table. Genes which fulfilled the criteria in all of the three comparisons are displayed in the shaded part of the table. Genes which fulfilled the criteria only in naive versus MOG 91-108 in CFA comparisons are not displayed here. LN cells were prepared as described (Weissert et al., 2001). cADPR, cyclic adenosine nucleotide ribose.
does CXCR4 (Mandala et al., 2002; Cyster, 2005; Lee et al., 2001; Brinkmann et al., 2002; Matloubian et al., 2004). We evaluated inhibition of Akt-dependent cell trafficking in MOG 91-108-immunized LEW.1AV1 (RT1^av1) rats. Disease was completely inhibited in rats treated from day 0 p.i. with FTY720 (n=10) as compared to the vehicle-treated controls (n=10, t-test, cumulative disease score P<0.0001) (Fig. 5A). Next, we tested the efficacy of FTY720 to treat established relapsing-remitting MOG 1-125-induced EAE in the DA (RT1^av1) rat. FTY720 treatment was started on day 21 p.i., after the first bout of disease (n=8), and showed a significant effect on the disease course as compared to vehicle treatment (n=8, t-test, cumulative disease score day 21-44 P<0.01) (Fig. 5B). To further examine the beneficial effect of FTY720 treatment on EAE, we boosted the rats with MOG 1-125 on day 44 after the first immunization. Although a relapse was induced in both groups, the DA rats under FTY720 treatment had a better clinical outcome compared to the vehicle-treated animals (t-test, cumulative disease score day 45-56 p.i., P<0.0001). On day 14 p.i., FTY720 treatment led to an increase of the relative size of the CD4 T-cell compartment (ANOVA, P<0.01) concurrent with a decrease in the CD8 T-cell (ANOVA, P<0.01) compartment (Fig. 5C; Fig. S1). FTY720 treatment (n=9) compared to controls (n=9) led to the downregulation of mRNA expression of its receptor, S1P1 (ANOVA, P<0.0001), and of Akt2 (ANOVA, P<0.0001), one of the genes involved in the intracellular signaling cascade connected to S1P1 and CXCR4, on day 14 p.i. Treatment also had a negative effect on the expression levels of Cd38 (ANOVA, P<0.0001). In contrast, the expression of Cxcr4 was not altered (ANOVA, not significant) (Fig. 5D).

**DISCUSSION**

In this study we identified gene networks that are crucially involved not only in raising an autoantigen-specific immune response but also in constituting encephalitogenicity. We analyzed the
expression and functional relevance of genes and their products expressed on lymphocytes after immunization with the encephalitogenic MOG 91-108 peptide in adjuvant, the non-encephalitogenic MOG 73-90 peptide in adjuvant, adjuvant alone or naive rats. Most interestingly, in the comparison of MOG 91-108 in adjuvant to MOG 73-90 in adjuvant immunized rats, compared to the other analyses, only a small number of genes were differentially expressed. These genes seem to be of major importance because they are genes involved in the encephalitogenic response leading to disease manifestation. From the overall expression data, we selected three genes that were upregulated in many comparisons: Cxcr4, Cd38 and Akt. We performed functional studies regarding these genes in EAE and analyzed tissue samples from individuals with MS.

CXCR4 (CD184) is a seven-transmembrane G-coupled receptor expressed by a number of tissues, including cells of the immune system (Campbell et al., 2003). Cxcr4-knockout mice die in utero or perinatally and do not only have defects in the hematopoietic system (impairment of myeloid and B-cell generation, reduced proliferation of triple-negative and double-positive lymphocytes), but also in the circulatory system and in the CNS (Zou et al., 1998; Tachibana et al., 1998). Overexpression of CXCR4 on T cells induces their accumulation in the bone marrow and reduction of these cells in the peripheral blood. CXCR4 signaling leads to a prolonged protein kinase B (AKT) and extracellular signal-regulated kinase 2 activation in T cells. AKT activation promotes cell survival and can act as a co-stimulation for T-cell activation (Tilton et al., 2000). CXCR4 has only one known cognate ligand, which is CXCL12. CXCL12 is constitutively produced by stromal and endothelial cells. CXCL12 activates numerous signaling pathways, such as
Fig. 5. Influence of FTY720 in EAE. (A) Female LEW.1AV1 (RT1av1) rats were immunized with MOG 1-125 in CFA. EAE was scored as follows: 0, no disease; 1, tail paralysis; 2, paraparesis; 3, paraplegia; 4, tetraparaplegia; 5, moribund or dead. FTY720 completely inhibited EAE in rats treated orally with 0.4 mg/kg body weight from day 0 p.i. daily (white triangles, n=10) compared to vehicle (PBS)-treated controls (black triangles, n=10) (t-test, cumulative disease score, \(P<0.0001\)). (B) Female DA (RT1\#r) rats treated orally with 0.4 mg/kg body weight FTY720 daily starting on day 21 p.i. after a first bout of disease (white triangles, n=8) showed a reduced disease course compared to vehicle (PBS)-treated controls (black triangles, n=8) (t-test, cumulative disease score day 21-44 p.i., \(P<0.01\)). On day 44 p.i., rats were boosted with MOG 1-125 in CFA. Both groups relapsed but with a better outcome for the FTY720-treated group (t-test, cumulative disease score day 45-56 p.i., \(P<0.0001\)). (C) FACS analysis of cells from draining lymph nodes (LNs) demonstrated an increase in relative size of the CD4 T-cell compartment and a decrease in the size of the CD8 and B-cell compartment in FTY720-treated (white bars, n=10) rats compared to controls (black bars, n=9) (ANOVA, \(*P<0.01\)) on day 14 p.i. (D) Expression of St1p1 (Edg1), Akt2, Cxcr4 and Cd38 was assessed in FTY720-treated rats (white bars, n=9) compared to vehicle-treated controls (black bars, n=9) by quantitative PCR. FTY720 treatment led to downregulation of St1p1 and Akt2 as well as Cd38, but not of Cxcr4 (ANOVA for all except Cxcr4, \(*P<0.0001\)) on day 14 p.i. from cells derived from LNs. Results are expressed as 2^{-ΔΔCT} values. Numbers are mean±s.e.m.

CD38 is a membrane-associated type II glycoprotein that acts both as a receptor and enzyme (Cockayne et al., 1998; Kato et al., 1999; Salmi and Jalkanen, 2005). As an enzyme it catalyzes NAD\(^+\) into cyclic ADP-ribose and further into ADP-ribose. It also regulates Ca\(^{2+}\) levels from ryanodine receptor stores. CD38 is expressed on a variety of myeloid and lymphoid cells. CD38 ligation in B cells leads to tyrosine phosphorylation of several intracellular proteins such as Syk, p85 of phosphatidylinositol-3 kinase and phospholipase C-γ (Silvennoinen et al., 1996). CD38 ligation in T cells results in phosphorylation of the Raf-1/MAP kinase and CD3-ζ/ZAP-70 signaling pathway (Zuber, 1995). Furthermore, it is involved in dendritic cell migration and adhesion between lymphocytes and endothelial cells (Partida-Sanchez et al., 2004). B6.129P2-Cd38tm1Lnd/J mice show a slight reduction of
antibody titers to T-cell-dependent antigens (Cockayne et al., 1998). Additionally, these mice had increased susceptibility to bacterial infections, which is thought to be caused by a defective chemotactic response of neutrophils towards bacteria, underscoring a role in innate immunity as well (Partida-Sanchez et al., 2001).

We induced EAE in Cd38-knockout mice (B6.129P2-Cd38tm1Lnd/J) and controls. Cd38-knockout mice had a reduced disease severity and lower autoantibody and T-cell responses as compared to the controls. These findings show the importance of CD38 in EAE and possibly MS. This work forms the basis for further analysis of the involved cellular compartments and regulation of human disease (Mayo et al., 2008; Lischke et al., 2013).

FTY720 is a potent drug that affects lymphocyte trafficking and homing. Our studies and studies by others (Brinkmann et al., 2002; Balatoni et al., 2007) showed a strong beneficial effect of FTY720 on EAE under various experimental settings. The drug was approved for treatment of MS (Kappos et al., 2010). We demonstrate that treatment of MOG-induced EAE with FTY720 impacts the gene expression of the genes that are involved in encephalitogenic immune responses. This further validates our approach. We measured changes in expression of Sip1, Akt2 and Cdx4. Interestingly, no changes in expression of Cxcr4 was observed. The reason for this is not fully understood and deserves further investigations.

In conclusion, in this study we have identified genes that are involved not only in raising autoantigen-specific immune responses but which constitute encephalitogenicity. The immunization with encephalitogenic peptides induces a network of genes involved in activation and migration of lymphocytes. Based on this platform, we have established the paramount importance of G-coupled proteins in encephalitogenicity of adaptive immune responses. We speculate that similar involvement might operate also in other autoimmune diseases and possibly in transplant rejection, thereby establishing common mechanisms. These pathways might be valuable targets of therapeutic approaches as we have shown attenuation of EAE after treatment with FTY720 or reduced EAE severity in CD38-deficient mice. These findings not only validate our gene expression data, but also underscore the importance of the rat EAE model in translational medicine.

MATERIALS AND METHODS

Animals and EAE induction

Female rats or mice, 10-14 weeks of age, were used in all experiments. LEW.1AV1 (RT1<sup>b</sup>) rats were obtained from Hans Hedrich (Central Animal Laboratory, Hannover Medical School, Hannover, Germany) and DA (RT1<sup>b</sup>) rats were obtained from Harlan Winkelmann (Borchen, Germany). Female B6.129P2-Cd38tm1Lnd/J mice and the appropriate controls (C57BL/6J 000664) were purchased from the Jackson Laboratory (Bar Harbor, USA).

Animals were bred and kept under specific pathogen-free conditions. Animals were injected intradermally at the base of the tail (rats) or both flanks (mice) with 100 µg of MOG 1-125 in PBS (50 µg) without the addition of Mycobacterium tuberculosis or with IFA or CFA alone. The clinical scoring was as follows: 0=no illness; 1=tail weakness or paralysis; 2=hind-leg paraparesis or hemiparalysis; 3=hind-leg paralysis or hemiparalysis; 4=tetraparesis or moribund. All experiments were approved by the regional board in Tübingen, Germany.

Human samples

Blood samples were obtained after consent from individuals with MS and controls. The characteristics of the MS individuals and controls are indicated in Tables S6 and S7. The research was approved by the Ethics Committee of the University of Tübingen in Germany (Permission 125/2001).

Isolation of CNS-infiltrating cells

Infiltrating cells from the CNS were prepared as described before (Weissert et al., 1998a, 2001). In brief, rats were perfused with cold PBS, and brains and spinal cords were dissected out on day 12 p.i. Subsequently, brains and spinal cords were homogenized in 10 ml 50% Percoll/0.1% BSA/1% glucose (Amersham Pharmacia Biotech) containing 500 U DNase type I (Life Technologies). Ten ml of 50% Percoll was added to each sample after homogenization. A discontinuous Percoll gradient was obtained by adding 7 ml of 63% Percoll below and 20 ml of 30% Percoll above the sample. Samples were centrifuged for 40 min at 1000 g at 4°C. Lymphocytes were collected from the 63/50% Percoll interface. The cells were subsequently washed twice in 15-25 ml PBS with centrifugation at 600 g for 15 min at 4°C.

Isolation of mononuclear cells from lymph nodes and spleens

Draining inguinal LNs and spleens were dissected out under deep anesthesia. LNs were disrupted and mononuclear cells (MNCs) washed twice in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Paisley, UK), resuspended in complete medium (CM) containing DMEM supplemented with 5% fetal calf serum (PAA Laboratories Linz, Austria), 1% penicillin/streptomycin (Life Technologies), 1% glucose (Amersham Pharmacia Biotech) and 50 µM 2-mercaptoethanol (Life Technologies), and flushed through a 70-µm plastic strainer (Falcon, BD Biosciences, Franklin Lakes, NJ). MNCs from spleen were prepared in the same way as from LNs with the difference that red blood cells were lysed with lysis buffer consisting of 0.15 M NH₄Cl, 10 mM KHCO₃ and 0.1 mM Na₂ EDTA at pH 7.4. CD4⁺ cells were isolated by anti-rat CD4 microbeads using MACS technology (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer’s instruction.

CD4⁺ cell purification

CD4⁺ cells from the LNs were purified by MACS (Miltenyi Biotech, Bergisch Gladbach, Germany) and subsequently analyzed by Affymetrix gene array for differential gene expression.

Spinal cord tissue

From PBS-perfused naïve rats or in DA rats immunized with either IFA, CFA, MOG 1-125 in IFA or MOG 1-125 in CFA, spinal cord tissue was dissected and homogenized and subsequently assessed for mRNA expression.

RNA preparation

Total RNA of brain-infiltrating leukocytes or lymphocytes or spinal cord tissue was isolated by using an RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The RNA quality was analyzed with a Bioanalyzer 2100 (Agilent, Palo Alto, CA).

Microarrays

Affymetrix microarrays of the type RG U34 A (Affymetrix Inc., Santa Clara, CA) representing approximately 7000 full-length genes and 1000 expressed sequence tag (EST) clusters were used. For the purified CD4⁺ cells, the rat expression set 230A (Affymetrix) containing about 30,000 features was used. For each array, samples from at least three rats were pooled. Biotin-labeled cRNA was prepared and hybridized to the arrays. In brief, double-stranded CDNA was synthesized from whole RNA using a superscript choice kit (Invitrogen) with a T7-(dT)24 primer (Metabion) and in vitro transcribed into biotin-labeled cRNA. After hybridization, gene
arrays were washed and stained by a fluids station (Affymetrix) and scanned by a confocal laser scanning microscope (Agilent).

The data were analyzed using the microarray suite software, micro DB, and data-mining tool (Affymetrix). Only genes and ESTs that were ‘present’ and gave a difference call of either ‘increase’ or ‘decrease’ according to the Affymetrix software were included in further analysis. The extent of differential expression is expressed as an SLR. For the tables, the cut-off was set to an SLR of 1 signifying a twofold change in expression. Doubles, ESTs and sequences not corresponding to a gene were not included in the tables.

**Real-time PCR**

To avoid amplification/detention of contaminating genomic DNA, extracted RNA was treated with RNase free DNase (Promega, Madison, WI). Subsequently, cDNA was synthesized by reverse transcription with Moloney murine leukemia virus reverse transcriptase and random pdN6 primers in the presence of RNase inhibitor (Promega). Amplification was performed on an Applied Biosystems Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) using a SYBR green protocol. Results were expressed as 2^(-ΔΔCT) values. The primer sequences 5’ to 3’ were as follows:

**Rat primers**

*Gapdh*: forward: GAGTGGTCCTCAGTGACTCAA reverse: CATTAGAGGAGGAAGAGGAAG

*S1p1*: forward: TAGCCGGACGCAAATTACAGC reverse: GCAGAGTGGAGAAGAGAGA

*Cxcr4*: forward: GATGGTGGTGTTCCAGTTCC reverse: AGGGCACAGCAAGTGTGTTG

*Cxcl12*: forward: CGATTCTTTGAGAGCCATGT reverse: AGGGCACAGTTTGGAGTGTT

*Cd38*: forward: AGGACACACTGCTGGGCTAT reverse: CAAAGTGGTTGGAGCAATTT

*Akt2*: forward: GAAGACTGAGAGGCCACGAC reverse: GGGAGCCACACTTGAATCC

**Human primers**

*h18s*: forward: CGGCTACCATCAGCAAGGGA reverse: GCCTGGAATTTACCGCGGCT

*Cxcr4*: forward: CATACGTCCTGGACCGCTACG reverse: GGATCCAGACGCAACATAG

**FACS**

FITC-conjugated monoclonal antibody (mAb) against CD45RA (OX-33) and TCRB (R73) and phycoerythrin (PE)-conjugated mAb against CD4 (OX-35) and MHC II (OX-6) and appropriate isotype controls were purchased from Becton Dickinson (Heidelberg, Germany). Flow cytometry was performed on a FACScalibur running with Cellquest software (Becton Dickinson). Cells were gated on the lymphocyte population in the forward scatter (FSC)-side scatter (SSC) dot plot. For data analysis, Flowing Software 2.5.1 (Turku Center for Biotechnology, Finland) was used.

**ELISA**

Serum taken at the time point of euthanasia was subject to an anti-MOG autoantibody ELISA. ELISA plates (96-well; Nunc, Roskilde, Denmark) were coated with 2.5 μg/ml (100 μl/well) MOG 1-125 overnight at 4°C. Plates were washed with PBS/0.05% Tween 20 and blocked with milk powder for 1 h at room temperature. After washing, diluted serum samples were added and plates were incubated for 1 h at room temperature. Then, plates were washed and rabbit anti-mouse antiserum (IgG, IgG1, IgG2a, IgG2b, IgG3, IgM; Nordic, Tilburg, The Netherlands) was added and incubated for 1 h at room temperature. Plates were washed prior to the addition of peroxidase-conjugated goat anti-rabbit antiserum (Nordic) diluted in PBS/0.05% Tween 20. After 30 min incubation, plates were washed and bound antibodies were visualized by addition of 2,2′azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) (Roche Diagnostics, Mannheim, Germany). After 15 min of incubation, optical density was read at 405 nm.

ELISA with human serum was performed according to the instructions of the manufacturer [Quantikine human SDF1alpha Immunoassay (R&D Systems, Minneapolis, MN)].

**Proliferation assay**

Cells from draining LNs were prepared as described above and cultured in the presence of rrMOG in 96-well plates as described by Weissert et al. (1998b). Cells were cultured for 48 h and pulsed with 1 μCi [3H]thymidine for the last 18 h. The incorporation of [3H]thymidine was measured using a beta-scintillation counter.

**FTY720 treatment**

Rats were treated with FTY720 (generous gift of Novartis AG, Switzerland) and received a daily dose of 0.4 mg/kg body weight in sterile water by oral gavage as described (Balatoni et al., 2007).

This article is part of a special subject collection ‘Spotlight on Rat: Translational Impact’, guest edited by Tim Altman and Aron Geurts. See related articles in this collection at http://dmm.biologists.org/collection/rat-disease-model.

**Acknowledgements**

We thank Thomas Weiss and Kerstin Stuck for excellent technical assistance.

**Competing interests**

The authors declare no competing or financial interests.

**Author contributions**

M.M.H. performed the gene arrays, data analysis, target validation in rats and revised the paper. S.B. performed the gene arrays, data analysis and the target validation. B.G. did the work on CD38 in mice. K.M.S. performed target validation studies in rats and analyzed the data. A.B. performed studies in individuals with MS and controls. R.W. designed the study, raised the funding, performed the data analysis, and wrote and revised the paper.

**Funding**

This study was supported by grants from the Interdisciplinary Centre for Clinical Research (Bundesministerium für Bildung und Forschung) (Fo. 01KS9602), and German Research Foundation (Deutsche Forschungsgemeinschaft) to R.W. (DFG We 1947).

**Supplementary information**

Supplementary information available online at http://dmm.biologists.org/lookup/doi/10.1242/dmm.025536.supplemental

**References**


